177 related articles for article (PubMed ID: 21184620)
1. Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies.
Hosoe M; Woessner R; Matsushima S; Lawrence D; Kramer B
Clin Drug Investig; 2011; 31(4):247-55. PubMed ID: 21184620
[TBL] [Abstract][Full Text] [Related]
2. Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD.
Beier J; Pujol H; Seoane B; Jimenez E; Astbury C; Massana E; Ruiz S; de Miquel G
BMC Pulm Med; 2016 Jul; 16(1):102. PubMed ID: 27439370
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
4. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
Laforce C; Aumann J; de Teresa Parreño L; Iqbal A; Young D; Owen R; Higgins M; Kramer B;
Pulm Pharmacol Ther; 2011 Feb; 24(1):162-8. PubMed ID: 20619353
[TBL] [Abstract][Full Text] [Related]
5. Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial.
Kato M; Makita H; Uemura K; Fukuchi Y; Hosoe M; Emery C; Higgins M; Kramer B
Allergol Int; 2010 Sep; 59(3):285-293. PubMed ID: 20567133
[TBL] [Abstract][Full Text] [Related]
6. Indacaterol: in chronic obstructive pulmonary disease.
Moen MD
Drugs; 2010 Dec; 70(17):2269-80. PubMed ID: 21080743
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study.
Feldman G; Siler T; Prasad N; Jack D; Piggott S; Owen R; Higgins M; Kramer B;
BMC Pulm Med; 2010 Mar; 10():11. PubMed ID: 20211002
[TBL] [Abstract][Full Text] [Related]
8. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.
Vogelmeier C; Ramos-Barbon D; Jack D; Piggott S; Owen R; Higgins M; Kramer B;
Respir Res; 2010 Oct; 11(1):135. PubMed ID: 20920365
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
Vincken W; Aumann J; Chen H; Henley M; McBryan D; Goyal P
Int J Chron Obstruct Pulmon Dis; 2014; 9():215-28. PubMed ID: 24596459
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
[TBL] [Abstract][Full Text] [Related]
12. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
Wedzicha JA; Buhl R; Lawrence D; Young D
Respir Med; 2015 Jan; 109(1):105-11. PubMed ID: 25433954
[TBL] [Abstract][Full Text] [Related]
13. Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.
Bleecker ER; Siler T; Owen R; Kramer B
Int J Chron Obstruct Pulmon Dis; 2011; 6():431-8. PubMed ID: 22003288
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of indacaterol in chronic obstructive pulmonary disease.
Ribeiro M; Chapman KR
Int J Chron Obstruct Pulmon Dis; 2012; 7():145-52. PubMed ID: 22419862
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study.
Shimada S; Vaidya S; Khindri S; Tashiro N; Cheng Y; Hara H; Majumdar T; Woessner R; Furihata K; Kobayashi K
Int J Clin Pharmacol Ther; 2015 May; 53(5):398-407. PubMed ID: 25740265
[TBL] [Abstract][Full Text] [Related]
17. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol.
Bauwens O; Ninane V; Van de Maele B; Firth R; Dong F; Owen R; Higgins M
Curr Med Res Opin; 2009 Feb; 25(2):463-70. PubMed ID: 19192991
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches.
Renard D; Looby M; Kramer B; Lawrence D; Morris D; Stanski DR
Respir Res; 2011 Apr; 12():54. PubMed ID: 21518459
[TBL] [Abstract][Full Text] [Related]
19. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
Beeh KM; Wagner F; Khindri S; Drollmann AF
COPD; 2011 Oct; 8(5):340-5. PubMed ID: 21793716
[TBL] [Abstract][Full Text] [Related]
20. Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease.
McKeage K
Drugs; 2012 Mar; 72(4):543-63. PubMed ID: 22356291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
